Cargando…

Can a Two-Dose Influenza Vaccine Regimen Better Protect Older Adults? An Agent-Based Modeling Study

Older adults (age ≥ 65) are at high risk of influenza morbidity and mortality. This study evaluated the impact of a hypothetical two-dose influenza vaccine regimen per season to reduce symptomatic flu cases by providing preseason (first dose) and mid-season (second dose) protection to offset waning...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams, Katherine V., Krauland, Mary G., Harrison, Lee H., Williams, John V., Roberts, Mark S., Zimmerman, Richard K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697266/
https://www.ncbi.nlm.nih.gov/pubmed/36366307
http://dx.doi.org/10.3390/vaccines10111799
_version_ 1784838518723313664
author Williams, Katherine V.
Krauland, Mary G.
Harrison, Lee H.
Williams, John V.
Roberts, Mark S.
Zimmerman, Richard K.
author_facet Williams, Katherine V.
Krauland, Mary G.
Harrison, Lee H.
Williams, John V.
Roberts, Mark S.
Zimmerman, Richard K.
author_sort Williams, Katherine V.
collection PubMed
description Older adults (age ≥ 65) are at high risk of influenza morbidity and mortality. This study evaluated the impact of a hypothetical two-dose influenza vaccine regimen per season to reduce symptomatic flu cases by providing preseason (first dose) and mid-season (second dose) protection to offset waning vaccine effectiveness (VE). The Framework for Reconstructing Epidemiological Dynamics (FRED), an agent-based modeling platform, was used to compare typical one-dose vaccination to a two-dose vaccination strategy. Primary models incorporated waning VE of 10% per month and varied influenza season timing (December through March) to estimate cases and hospitalizations in older adults. Additional scenarios modeled reductions in uptake and VE of the second dose, and overall waning. In seasons with later peaks, two vaccine doses had the largest potential to reduce cases (14.4% with February peak, 18.7% with March peak) and hospitalizations (13.1% with February peak, 16.8% with March peak). Reductions in cases and hospitalizations still resulted but decreased when 30% of individuals failed to receive a second dose, second dose VE was reduced, or overall waning was reduced to 7% per month. Agent-based modeling indicates that two influenza vaccine doses could decrease cases and hospitalizations in older individuals. The highest impact occurred in the more frequently observed late-peak seasons. The beneficial impact of the two-dose regimen persisted despite model scenarios of reduced uptake of the second dose, decreased VE of the second dose, or overall VE waning.
format Online
Article
Text
id pubmed-9697266
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96972662022-11-26 Can a Two-Dose Influenza Vaccine Regimen Better Protect Older Adults? An Agent-Based Modeling Study Williams, Katherine V. Krauland, Mary G. Harrison, Lee H. Williams, John V. Roberts, Mark S. Zimmerman, Richard K. Vaccines (Basel) Article Older adults (age ≥ 65) are at high risk of influenza morbidity and mortality. This study evaluated the impact of a hypothetical two-dose influenza vaccine regimen per season to reduce symptomatic flu cases by providing preseason (first dose) and mid-season (second dose) protection to offset waning vaccine effectiveness (VE). The Framework for Reconstructing Epidemiological Dynamics (FRED), an agent-based modeling platform, was used to compare typical one-dose vaccination to a two-dose vaccination strategy. Primary models incorporated waning VE of 10% per month and varied influenza season timing (December through March) to estimate cases and hospitalizations in older adults. Additional scenarios modeled reductions in uptake and VE of the second dose, and overall waning. In seasons with later peaks, two vaccine doses had the largest potential to reduce cases (14.4% with February peak, 18.7% with March peak) and hospitalizations (13.1% with February peak, 16.8% with March peak). Reductions in cases and hospitalizations still resulted but decreased when 30% of individuals failed to receive a second dose, second dose VE was reduced, or overall waning was reduced to 7% per month. Agent-based modeling indicates that two influenza vaccine doses could decrease cases and hospitalizations in older individuals. The highest impact occurred in the more frequently observed late-peak seasons. The beneficial impact of the two-dose regimen persisted despite model scenarios of reduced uptake of the second dose, decreased VE of the second dose, or overall VE waning. MDPI 2022-10-26 /pmc/articles/PMC9697266/ /pubmed/36366307 http://dx.doi.org/10.3390/vaccines10111799 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Williams, Katherine V.
Krauland, Mary G.
Harrison, Lee H.
Williams, John V.
Roberts, Mark S.
Zimmerman, Richard K.
Can a Two-Dose Influenza Vaccine Regimen Better Protect Older Adults? An Agent-Based Modeling Study
title Can a Two-Dose Influenza Vaccine Regimen Better Protect Older Adults? An Agent-Based Modeling Study
title_full Can a Two-Dose Influenza Vaccine Regimen Better Protect Older Adults? An Agent-Based Modeling Study
title_fullStr Can a Two-Dose Influenza Vaccine Regimen Better Protect Older Adults? An Agent-Based Modeling Study
title_full_unstemmed Can a Two-Dose Influenza Vaccine Regimen Better Protect Older Adults? An Agent-Based Modeling Study
title_short Can a Two-Dose Influenza Vaccine Regimen Better Protect Older Adults? An Agent-Based Modeling Study
title_sort can a two-dose influenza vaccine regimen better protect older adults? an agent-based modeling study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697266/
https://www.ncbi.nlm.nih.gov/pubmed/36366307
http://dx.doi.org/10.3390/vaccines10111799
work_keys_str_mv AT williamskatherinev canatwodoseinfluenzavaccineregimenbetterprotectolderadultsanagentbasedmodelingstudy
AT kraulandmaryg canatwodoseinfluenzavaccineregimenbetterprotectolderadultsanagentbasedmodelingstudy
AT harrisonleeh canatwodoseinfluenzavaccineregimenbetterprotectolderadultsanagentbasedmodelingstudy
AT williamsjohnv canatwodoseinfluenzavaccineregimenbetterprotectolderadultsanagentbasedmodelingstudy
AT robertsmarks canatwodoseinfluenzavaccineregimenbetterprotectolderadultsanagentbasedmodelingstudy
AT zimmermanrichardk canatwodoseinfluenzavaccineregimenbetterprotectolderadultsanagentbasedmodelingstudy